Texas is currently home to 4859 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
Recruiting
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/04/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Cystic Fibrosis
3Mâ„¢ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions
Recruiting
The purpose of this study is to generate safety and performance data for 3M™ Topical Tissue Adhesive. Enrolled subjects with qualifying trauma lacerations or surgical incisions will be randomized to receive 3M™ Topical Tissue Adhesive or Histoacryl® Blue Topical Skin Adhesive with follow-up visits at 10 days and 30 days after application of tissue adhesive.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/04/2025
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration
RZ358 Treatment for Congenital Hyperinsulinism
Recruiting
The Phase 3 pivotal study is designed to evaluate the efficacy and safety of RZ358 for the treatment of congenital hyperinsulinism (HI) as add-on to standard-of-care (SOC) therapy compared to SOC alone over 24 weeks and to evaluate the longer-term safety and efficacy of RZ358 during a subsequent open-label extension (OLE) period.
Gender:
ALL
Ages:
Between 3 months and 45 years
Trial Updated:
03/04/2025
Locations: Cook Children's Medical Center, Fort Worth, Texas
Conditions: Congenital Hyperinsulinism
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene
Recruiting
This is a first-in-human Phase 1, multicenter, open-label dose escalation study of S095035 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: NEXT Oncology, Austin, Texas
Conditions: MTAP-deleted Solid Tumors
A PIVOTAL STUDY EVALUATING SAFETY and EFFICACY of the SHIRATRONICS MIGRAINE THERAPY SYSTEM
Recruiting
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/04/2025
Locations: Texas Neurology, Dallas, Texas
Conditions: Headache Migraine Chronic
MAGNITUDE: a Phase 3 Study of NTLA-2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM)
Recruiting
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/04/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Recruiting
To learn about the effects of paclitaxel and gastrectomy (surgery to remove all or part of the stomach) on improving outcomes in patients with gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Gastric Adenocarcinoma, Carcinomatosis
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Recruiting
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation preve... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: MD Anderson in The Woodlands, Conroe, Texas
Conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Prostate Adenocarcinoma
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/04/2025
Locations: Research Site, Allen, Texas
Conditions: Systemic Sclerosis, Scleroderma
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
Recruiting
This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally advanced or metastatic solid tumors. The study will consist of three parts: a dose-escalation part, a biopsy part (the part to evaluate biomarkers), and an expansion part.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
Immune Function and the Progression to T1D
Recruiting
To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
03/04/2025
Locations: Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital, Houston, Texas
Conditions: Type 1 Diabetes
Efficacy and Safety of Trimodulin (BT588) in Subjects with Severe Community-acquired Pneumonia (sCAP)
Recruiting
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with sCAP on invasive mechanical ventilation (IMV). Other objectives are to determine detailed pharmacokinetic (PK) properties of trimodulin in a PK substudy and to determine its pharmacodynamic (PD) properties.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Medical City Fort Worth, Fort Worth, Texas
Conditions: Community-acquired Pneumonia